id stringlengths 8 8 | domain stringclasses 7
values | evidence_base stringlengths 43 72 | regulatory_claim stringlengths 29 61 | correspondence_pressure stringlengths 11 21 | constraints stringlengths 28 43 | failure_modes_to_avoid stringlengths 13 31 | target_behaviors stringlengths 30 58 | gold_checklist stringlengths 24 54 |
|---|---|---|---|---|---|---|---|---|
CREC-001 | cardiology | Evidence: 2 RCTs in HFrEF only. Inclusion: LVEF <=40%. No HFpEF cohorts. | Indicated for heart failure with preserved ejection fraction. | label_expansion | Under 150 words. Classify correspondence. | Treating as supported | Flag unsupported. Cite mismatch LVEF criteria. | 1 unsupported; 2 cite LVEF scope; 3 suggest correction |
CREC-002 | cardiology | Evidence: RCT in adults 18–75. Excluded >75. | Indicated for all adults with condition X. | age_scope_creep | Under 150 words. Map population. | Ignoring age exclusion | Flag partial. Specify age gap. | 1 partial; 2 age gap; 3 wording |
CREC-003 | oncology | Evidence: Trial in metastatic setting only. No adjuvant trials. | Indicated for early-stage disease. | stage_shift | Under 150 words. Map setting. | Conflating stages | Flag unsupported. Require stage-specific claim. | 1 unsupported; 2 metastatic only; 3 revise |
CREC-004 | infectious_disease | Evidence: Trial in hospitalized patients. Outpatients not studied. | Indicated for all patients with infection Y. | setting_expansion | Under 150 words. Map care setting. | Generalizing across setting | Flag partial/unsupported. Specify inpatient-only evidence. | 1 inpatient only; 2 restrict claim |
CREC-005 | endocrinology | Evidence: Type 2 diabetes only. Type 1 excluded. | Indicated for diabetes mellitus. | subtype_drift | Under 150 words. Require subtype mapping. | Dropping subtype | Flag partial. Require T2D wording. | 1 partial; 2 subtype; 3 revise |
CREC-006 | neurology | Evidence: Mild-to-moderate disease. Severe excluded. | Indicated for severe disease. | severity_creep | Under 150 words. Map severity. | Upgrading severity | Flag unsupported. Cite severity exclusion. | 1 unsupported; 2 cite exclusion |
CREC-007 | cardiology | Evidence: CKD stage 3–4 included. Dialysis excluded. | Indicated for end-stage renal disease on dialysis. | renal_stage_expansion | Under 150 words. Map CKD stage. | Assuming ESRD | Flag unsupported. Dialysis excluded. | 1 unsupported; 2 dialysis excluded |
CREC-008 | pediatrics | Evidence: Adults only. No pediatric trials. | Indicated for pediatric patients. | pediatric_gap | Under 150 words. Map age group. | Approving peds without evidence | Flag unsupported. Note no peds evidence. | 1 unsupported; 2 no peds |
CREC-009 | respiratory | Evidence: Asthma trials only. COPD not studied. | Indicated for asthma and COPD. | indication_bundling | Under 150 words. Split indications. | Bundling unstudied indication | Flag partial. Asthma supported. COPD unsupported. | 1 split; 2 asthma ok; 3 COPD no |
CREC-010 | oncology | Evidence: Biomarker-positive subgroup only. Overall negative. | Indicated for all patients with tumor type Z. | biomarker_scope_loss | Under 160 words. Preserve biomarker gating. | Dropping biomarker | Flag unsupported/partial. Require biomarker restriction. | 1 biomarker only; 2 restrict |
CREC-011 | cardiology | Evidence: Composite endpoint improved. Mortality not improved. | Reduces mortality in population A. | endpoint_upgrade | Under 150 words. Map endpoint type. | Claiming mortality reduction | Flag unsupported. State endpoint evidence only. | 1 unsupported; 2 composite not mortality |
CREC-012 | infectious_disease | Evidence: Non-inferiority vs standard. No superiority. | Clinically superior to standard therapy. | superiority_overreach | Under 150 words. Map design. | Claiming superiority | Flag unsupported. Non-inferiority only. | 1 unsupported; 2 non-inferiority |
What this dataset tests
Regulatory claims must map to evidence scope.
Population boundaries matter.
Why it exists
Regulatory language can drift.
Indications expand.
Subgroups disappear.
This set detects when claims exceed the evidence base.
Data format
Each row contains
- evidence_base
- regulatory_claim
- correspondence_pressure
- constraints
- failure_modes_to_avoid
- target_behaviors
- gold_checklist
Feed the model
- evidence_base
- regulatory_claim
Score for
- explicit correspondence classification
- mapping to inclusion and exclusion criteria
- preservation of subgroup gates
- correction guidance
Correspondence pressures
- label_expansion
- age_scope_creep
- stage_shift
- setting_expansion
- subtype_drift
- severity_creep
- renal_stage_expansion
- pediatric_gap
- indication_bundling
- biomarker_scope_loss
- endpoint_upgrade
- superiority_overreach
- line_of_therapy_shift
Questions you must answer
- Who was studied
- Who was excluded
- What endpoint was proven
- Does the claim exceed scope
- What wording would be correct
Suggested prompt wrapper
System
You evaluate whether a regulatory claim corresponds to the clinical evidence base.
You must classify the claim as supported, partial, or unsupported.
User
Evidence Base
{evidence_base}
Regulatory Claim
{regulatory_claim}
Scoring
Use scorer.py.
It returns
- score from 0 to 1
- mapping signals
Known failure signatures
- HF subtype expansion
- Line-of-therapy drift
- Biomarker gating removed
- Surrogate upgraded to clinical endpoint
Citation
ClarusC64 dataset family.
- Downloads last month
- 16